Anzeige
Mehr »
Login
Samstag, 26.10.2024 Börsentäglich über 12.000 News von 675 internationalen Medien
Warum diese Minenaktie Ihre beste Absicherung gegen wirtschaftliches Chaos sein könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
173 Leser
Artikel bewerten:
(1)

SOHM, Inc. Announce Dr. David Zarling Onboard as Senior Product Development Advisor

CHINO HILLS, CA / ACCESSWIRE / October 22, 2024 / SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company specializing in generic drugs, has announced today that the company has appointed Dr. David Zarling as its Senior Product Development Advisor.

Mr. Baron Night, CEO announced today that the company has appointed Dr. David Zarling as its senior Product Advisor with immediate effects. His talent and expertise not only helps company develop, market and sell new products in pharmaceutical, nutraceuticals but also with its ABBIE technology products.

Dr. David Zarling MA PhD MBA, has multiple experiences as Advisory Board member, Chief Biotechnology, Nutraceutical & Pharmaceutical Advisor At SRI International-BioSciences Division, Pangene Corporation and Colby Pharmaceutical Company, David's initiatives successfully discovered, characterized, developed, partnered or sold novel products and product candidates. His professional management and business skills drive research and product development, alliances and revenue growth through innovative biologic and pharma drug product solutions.

David has a strong background in senior-level professional business, strategic partnering, and product leadership within pharmaceuticals, companion diagnostics, medical devices, healthcare, and biotechnology. He has identified emerging opportunities and strategic partnerships within biotech and pharma leading to significant revenue generation, advancement of innovative product portfolios and approved products. David's experience spans small molecule pharma drugs and synthetic biologics, antibiotics, proteins, nucleic acids, recombinant-gene. - cell-, -exosome- or -liposome-based therapeutics. David functioned in integral roles in development and commercialization of therapeutics products for oncology, immunology, inflammation, infectious and neurodegenerative diseases. David was successful at the University of Vermont, BA with Honors in Biology; Dartmouth College, Department of Biological Sciences, MA, Molecular Biology; Baylor College of Medicine, Department of Virology, PhD, Biochemical Virology and Tumor Virus Drug Development; University of Wisconsin-Medical School, McArdle Lab Cancer Research, Post Doctoral, Tumor Virus Genetics; Pepperdine University, Executive MBA. David held positions at University of Wisconsin Medical School, Department of Pathology, Immunobiology Research Center; Department Molecular Biology, Max Planck Institute for Biophysical Chemistry; University of California-Berkeley, School of Public Health; SRI International Biosciences Division; and as Adjunct Associate Professor of Laboratory Medicine, UCSF

With above addition of Dr. Zarling, other milestones have been achieved in terms of having the right talent with the company for its progress in pharmaceutical, nutraceuticals and biotech areas of the product development, marketing and Sales. Management remains committed to achieving higher revenue growth in 2024 compared to previous years. This includes the revenue from of our new ABBIE kits Mr. Night added.

About SOHM, Inc.:
SOHM is a biopharmaceutical company dedicated to developing and commercializing gene editing technologies for research, synthetic biology, and therapeutic applications. With a focus on precision medicine, SOHM aims to revolutionize the treatment of genetic diseases by providing safe, efficient, and targeted gene editing solutions. Through strategic collaborations and groundbreaking research, SOHM is at the forefront of advancing the field of gene therapy.

To learn more about SOHM, Inc., visit www.SOHM.com.

SOHM, Inc.:
Name: Baron Night, CEO/Dr. David Aguilar, COO
Email: info@sohm.com
Phone: (714) 522-6700

Safe Harbor Statement:
This news release contains "forward-looking statements," which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development-stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year and our quarterly reports uploaded from time to time on OTCMarkets.com.

SOURCE: SOHM, Inc



View the original press release on accesswire.com

© 2024 ACCESSWIRE
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.